Skip to main content
EURAXESS

Postdoctoral fellow in nanomedicine (M/W)

CNRS - National Center for Scientific Research The Human Resources Strategy for Researchers
21 Dec 2023

Job Information

Organisation/Company
CNRS
Department
Institut Pluridisciplinaire Hubert Curien
Research Field
Chemistry » Physical chemistry
Chemistry » Computational chemistry
Researcher Profile
Recognised Researcher (R2)
Country
France
Application Deadline
Type of Contract
Temporary
Job Status
Full-time
Hours Per Week
35
Offer Starting Date
Is the job funded through the EU Research Framework Programme?
HE / ERC
Is the Job related to staff position within a Research Infrastructure?
No

Offer Description

A wide array of immunotherapies have been developed throughout the last decade to stimulate the body's immune system to fight cancer. These early immunotherapies, primarily using T-cells, and including "checkpoint blockade" and "CAR-T cell" therapies, demonstrated great success in enhanc-ing the efficacy of melanoma and hematologic cancers treatments. However, their therapeutic effi-cacies had limitations in most of the solid cancers. Like T-cells, natural killer (NK) cells are part of the body's natural immune system and have the ability to recognize and directly destroy cancer cells in a broad range of indications. It has been observed that NK cells permit an enhanced tumor pene-tration as compared to T cells, offering an alternative therapeutic avenue. More importantly, NK cells amplify the effectiveness of T-cells, acting as a sentinel that calls other immune system cells to attack cancer cells. They also broaden the therapeutic window (or "safety profile") thanks to their ability to distinguish cancer cells from the other cells in the body, which allows better targeting.

Throughout this project, our goal is to dramatically enhance immunotherapy using a click-ready mul-ti-specific immune cell engager combining the activation of either T cells or NK cells, to co-stimulate these immune cells, and hence improve their ability to recognize the tumor cells. By developing a modular platform with optimized biodistribution properties engaging the immune system, we seek to expand the screening of multi-specific cells but also to reduce the cost of development of bi- and tri-specific antibodies. The design of the platform and the proof-of-concept will be validated against Multiple Myeloma, the most common hematologic cancer, with the development of a bi- and tri-specific T cell engager.

• To develop a novel in vivo targeted approach for immune cell engagement based on the concept of multispecific antibodies
• To synthesize the antibodies to enable the immune cell engagements
• To validate biologically the antibodies at the in vitro and in vivo levels
• To disseminate the results of the study through publications and participation at national and international conferences
• To supervise master student
• To participate to grant writing application for national and European calls

The Institut Pluridisciplinaire Hubert CURIEN (IPHC), a joint research unit under the joint supervision of CNRS and the University of Strasbourg (UMR7178), is a multidisciplinary laboratory where research teams from different scientific cultures (ecology, physiology and ethology, chemistry and subatomic physics) develop very high level programs based on scientific instrumentation. The IPHC is structured into 4 departments and has a total staff of 393 staff including 257 permanent staff (ie 119 researchers and teachers / researchers and 138 engineers and technicians), 46 staff on fixed-term contracts and 90 doctoral students.
The postdoctoral fellow will work in the IPHC's Department of Analytical Sciences (DSA), report to DETAPPE Alexandre and be based at the Institut de Cancérologie Strasbourg Europe and the IPHC, in collaboration with the group of Loic Charbonnière.
With about 4 postdoctoral fellows, 5 PhD students, 1 laboratory manager, multiple master 2 students, and 4 physicians, the laboratory develops novel drug delivery systems, antibody drug conjugates, immuno-nanotherapies with the ultimate goal to translate these findings to the clinic through the Institut de Cancérologie Strasbourg Europe. The laboratory is collaborating with various groups at the national level and with international laboratories (Dana-Farber, ETH Zurich, Technical University of Denmark). The postdoctoral fellow will benefit from a dynamic environment with various backgrounds, allowing a fast-pace research.

Requirements

Research Field
Chemistry
Education Level
PhD or equivalent
Research Field
Chemistry
Education Level
PhD or equivalent
Languages
FRENCH
Level
Basic
Research Field
Chemistry » Physical chemistry
Years of Research Experience
1 - 4
Research Field
Chemistry » Computational chemistry
Years of Research Experience
1 - 4

Additional Information

Eligibility criteria

- A PhD degree in molecular biology, nanomedicine or equivalent with a strong background in drug development
- Oral and written scientific skills at level B2 according to the Common European Framework of Reference for Languages
- Strong team-work abilities through international partnerships (participation to a collaborative project, scientific meetings, travels)
- Experience in cell culture, including myeloma and/or breast cancer cell culture and primary cells
- Experience in molecular biology basics (FACS, western blot, cell sorting of primary cells, RTqPCR)

Website for additional job details

Work Location(s)

Number of offers available
1
Company/Institute
Institut Pluridisciplinaire Hubert Curien
Country
France
City
STRASBOURG
Geofield

Contact

City
STRASBOURG
Website